Beta Pharma Inc. was founded in 1996 as a contract research organization (named Beta Chemicals Inc.) to provide custom synthesis service for the pharmaceutical and biotechnology R&D community. In 2003, Beta Pharma Inc. established a joint-venture with an investor group to form Zhejiang Beta Pharma Inc. in China. In May of 2006, a novel EGFR inhibitor, Icotinib, entered into a Phase I clinical trial in China. The randomized, double blind and multi-center Phase III clinical trial of Icotinib is complete, and the regulatory filing has been submitted. The SFDA approved Icotinib on June 7, 2011.

Click here to learn more about Icotinib

Today, Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development and commercialization of innovative late stage therapies targeting oncology. Our oncology products pipeline is diverse and undergoing rapid development.

................................................................................................................................................................................................................................................
 
Home  |  About Us  |  Product Pipeline  |  Services  |  News Center  |  Business Corporation  |  Contact Us  |  Sitemap
Beta Pharma Inc.@ 2010 | Website Design By Triad Web Design